TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results

~ Signs Letter of Intent with Felix Biotechnology to license Thin Film Freezing technology for their bacteriophage products for lung inhalation ~ ~ Signs worldwide co-development agreement with Augmenta Bioworks for monoclonal antibody therapeutics ~ ~ Reports positive preclinical immunogenicity and efficacy for dry powder universal influenza formulation in collaboration with the University of Georgia ~ ~ Reports positive Phase I initial efficacy data on Tacrolimus Inhalation Powder; Voriconazole Inhalation Powder program progresses to Phase II trial ~